Microbiome Sample Preparation Technology Market (By Product: Instruments, Consumables; By Workflow; By Application; By Disease Type; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global microbiome sample preparation technology market size was estimated at around USD 242.13 million in 2021 and it is projected to hit around USD 411.97 million by 2030, growing at a CAGR of 6.08% from 2022 to 2030.

Report Highlights

• The consumables segment accounted for the largest share of over 85.07% in 2021 and is anticipated to maintain a similar trend during the forecast period. 
• Sample extraction/isolation held the largest share of over 20.04% in 2021. 
• The DNA sequencing segment held the largest share of over 25.14% in 2021. 
• Gastrointestinal disorders captured the largest revenue share of over 50.21% in 2021. 
• The diagnostic labs segment held the largest revenue share of over 60.04% in 2021.
• North America held the dominant share of over 40.06% in 2021. 

The rising importance of the microbiome as an area of study for Inflammatory Bowel Disease (IBD) research along with the innovation in genome sequencing techniques are significant contributors to the market growth. Crohn's disease is one of the most common diseases of IBD and surging incidence rates in North America and Western Europe, with approximately 100 to 300 per 100,000 people being affected in both regions, are likely to accelerate the R&D for the same.

A metabolite-based treatment method is highly promising for Dysbiosis, despite its existing limitations. Within coming years, researchers are anticipated to require to incorporate metabolomics characterization of the microbial ecosystem into their standard toolkit, enabling the community to define functional signatures for disease states that have previously only been linked to compositional and metagenomic changes.

Additionally, the development of novel metabolite sensors will eventually allow for the targeted regulation of downstream signaling cascades in circumstances when the host's reaction to the microbiome is excessive. Metabolite-based treatments provide a direct and actionable way to combat the host effects of dysbiosis. The era of metabolite research in microbiome science has already begun, and sustained efforts could lead to the discovery of clinically applicable therapeutics for dysbiosis-related disorders.

Other factors such as the rising penetration of personalized medicine are likely to impact the usage of microbiome sample preparation technology. Various research institutes are conducting studies to understand the gut microbiome and its impact on diet followed by the identification of effective therapeutics. For instance, a study was carried out in 2019 at the Weizmann Institute of Science to develop an algorithm based on machine learning and study glycemic response after consuming similar food. The study concluded that patients displayed different glycemic responses, even when food consumed is the same as microbiome played an important determinant of the blood sugar levels than genetic data.

The COVID-19 pandemic accelerated the use of microbiome sample preparation technology for the research proposed. There have been various studies in progress focusing on the alteration of gut microbiome post-COVID-19 infection. According to studies, the abundance of phyla Firmicutes, Bacteroidetes, and Proteobacteria were observed within patients diagnosed with the virus. Furthermore, fecal metabolomic studies in COVID-19 patients have revealed probable amino acid-related pathways that link gut microbiota to inflammation.

However, the high cost of instruments in this market is anticipated to have adverse effects on the growth rate. Emerging nations with low spending capability on healthcare and sanitation are observed to have a high risk of gastrointestinal disorders. With the potential high risk of infection in the population, low penetration of technology within these regions is likely to act as a market restraint within specific countries.

Scope of The Report

Product Insights

The consumables segment accounted for the largest share of over 85.07% in 2021 and is anticipated to maintain a similar trend during the forecast period. This is driven by the increasing demand for purification/extraction kits and DNA library preparation kits during COVID-19.

For instance, in June 2021, SpeeDx Pty, Ltd., an Australia-based company specializing in molecular diagnostics solutions, and MolGen, an innovative provider of DNA/RNA extraction technology, collaborated for the supply and distribution of their products across Europe and the Asia Pacific. The partnership is set to benefit both companies by combining MolGen's DNA/RNA extraction portfolio along with SpeeDx's diagnostic assay technology.

Instruments are anticipated to exhibit a stable and steady growth rate during the forecast period as the purchase frequency by the end-users of the product is low owing to a longer lifespan than consumables. Innovations in this domain include automated systems such as Maxwell RSC and Maxwell RSC 48 Instrument, which can work on preprogrammed methods and simultaneously process up to 16 and 48 samples, respectively, thus anticipated to improve the growth rate.

Workflow Insights

Sample extraction/isolation held the largest share of over 20.04% in 2021. Microbiome research is one of the important focus areas for ongoing studies in medicine and diagnostics to understand the impact of the microbiome on human health Studies in this domain rely on robust extraction methods that can provide efficient DNA extraction and eliminate inhibitory constituents from the sample. The extraction method used can vary based on the composition of the sample as certain cell types may require harsher methods for efficient extraction.

For instance, MGI Tech Co. offers a DNA extraction kit for purifying and extracting high-quality microbial genomic DNA from frozen and fresh human stool samples. It can be used for numerous areas, such as intestinal flora research, metagenomics analysis, and probiotics research. The product is applicable for PCR, metagenomics sequencing, and RT-PCR.

Library preparation is considered to be the most next-generation sequencing platform that requires ligation of adapters to the fragment ends. The fragmented DNA is subjected to end repair to form blunt ends followed by attachment of the deoxyadenosine 5′-monophosphate (dAMP) tail to the 3' end, for applications in the Illumina platform. The tail is required for avoiding concatamer formation and it facilitates ligation of adaptors having complementary dT overhangs.

Application Insights

The DNA sequencing segment held the largest share of over 25.14% in 2021. Sequencing is essential to various fields, ranging from basic biology to human evolution. Moreover, technological advancements that assure cost-effective sequencing are expected to support market growth.

For instance, in June 2022, a start-up company, Ultima Genomics stated at a meeting in Florida that with the advancement of existing technology, the company can offer human genomes for USD 100, which is one-fifth of the existing rate. However, at present, the majority of the market is captured by Illumina.

The metagenomic segment is anticipated to record the fastest growth rate during the forecasted period. The metagenomics approach can offer the identification of a wide range of pathogens, including novel and rare pathogens, and facilitate the characterization of the microbiome. Along with that, additional insights about disease epidemiology, the phylogeny of causative agents, and aid in the development of diagnostic tests for novel agents are fueling growth. The increasing scope of metagenomics is anticipated to supplement segment growth.

Disease Type Insights

Gastrointestinal disorders captured the largest revenue share of over 50.21% in 2021. The majority of the GI issues such as IBS, C. difficile, and Crohn's disease can be diagnosed using microbiome sample analysis. IBD, which includes ulcerative colitis (UC) and Crohn's disease (CD), is a relapsing-remitting gastrointestinal inflammatory illness that causes varying degrees of intestine damage and can lead to local and extra-intestinal problems.

The autoimmune disorder segment is expected to grow at the fastest rate during the forecast period and support the overall growth of the market. Autoimmune disorders have been a key area of research and one of the most emerging fields of medical sciences across the globe. For instance, a study published in January 2022 assessed the association between autoimmune diseases and gut microbiota. The study stated that the relationship between CeD andT1D and Bifidobacterium genus offered significant insights into the gut microbiota-mediated development process of autoimmune disorder.

End-use Insights

The diagnostic labs segment held the largest revenue share of over 60.04% in 2021 as the diagnostics lab is one of the key segments where in microbiome sampling finds its application. Being said, it is used in the diagnosis of autoimmune disorders, various types of cancers, gastrointestinal disorders, and many other medical conditions. The rising number of clinical trials analyzing microbial samples in order to diagnose various medical conditions is also a key growth factor.

The involvement of pharmaceutical and biotechnology companies in the market is at a moderate rate. However, the increasing investment in the market is anticipated to attract key new players to the market. For instance, as of march 2020, microbiome therapies and diagnostic firms have received a total of USD 4.49 billion in funding. The majority of these transactions occurred between 2014 and 2019, with nearly 300 different investment entities participating in over 80% of the 233 finance rounds reported and 90% of the monies committed in the last five years.

Regional Insights

North America held the dominant share of over 40.06% in 2021. This major share can be the result of rising funding opportunities, partnerships and collaborative efforts by the regional players, and the expanding use of technological developments in the U.S. For instance, Persephone Biosciences, a microbiome research firm, entered into an agreement with Janssen Biotech in Sep 2021, for the use of patient samples from Janssen’s cancer clinical trial. Furthermore, the increased usage of instruments and consumables in the North American market has been attributed to the high penetration of genomic research projects in the pipeline throughout the region.

The Asia Pacific is anticipated to be the fastest-growing region over the forecast period due to the significant commercial growth of new start-ups and the strategic decisions of multinational entities. For instance, in South Korea, CJ CheilJedang invested 4 billion won (USD3.56 million) in 2019 in KO Biolabs, which is developing microbiome-based psoriasis and asthma treatments. In July 2021, the company also acquired a 44% stake at 98.3 billion won in ChunLab, a provider of microbiome precision analysis technology.

Key Players

• QIAGEN
• BGI
• Bio-Rad Laboratories, Inc.
• Perkin Elmer, Inc.
• Agilent Technologies Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation

Market Segmentation

• By Product Outlook
• Instruments

• Extraction System
• Workstation
• Liquid Handling Instrument
• Other Sample Preparation Instruments
• Consumables
• Purification/Extraction Kits
• Library prep kits

• DNA Library Preparation Kits
• RNA Library Preparation Kits
• Library Quantitation & Amplification kits
• Clean-up and Selection Kits
• Microbiome DNA Enrichment
• Others
• By Workflow Outlook
• Sample Extraction/Isolation
• Sample Quantification
• Quality Control
• Fragmentation
• Library Preparation
• Target Enrichment
• Library Quantification
• Pooling
• By Application Outlook
• DNA Sequencing
• Whole-Genome Sequencing
• RNA Sequencing
• Methylation Sequencing
• Metagenomics
• Single Cell Sequencing
• Others
• By Disease Type Outlook
• Autoimmune Disorder
• Cancer
• Gastrointestinal Disorders
• Others
• By End-use Outlook
• Pharmaceutical & Biotechnology
• Diagnostic Labs
• Others
• By Regional Outlook
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE